|
a |
|
b/processing/MACCROBAT/21067996.ann |
|
|
1 |
T1 Age 2 13 41-year-old |
|
|
2 |
T2 Sex 14 17 man |
|
|
3 |
T3 Sign_symptom 23 34 weight loss |
|
|
4 |
E1 Sign_symptom:T3 |
|
|
5 |
T4 Sign_symptom 36 42 nausea |
|
|
6 |
E2 Sign_symptom:T4 |
|
|
7 |
T5 Sign_symptom 44 52 vomiting |
|
|
8 |
E3 Sign_symptom:T5 |
|
|
9 |
T6 Sign_symptom 68 72 pain |
|
|
10 |
E4 Sign_symptom:T6 |
|
|
11 |
T7 Biological_structure 58 67 abdominal |
|
|
12 |
R1 MODIFY Arg1:T7 Arg2:E4 |
|
|
13 |
T8 Clinical_event 77 85 referred |
|
|
14 |
E5 Clinical_event:T8 |
|
|
15 |
T9 Diagnostic_procedure 103 110 CT scan |
|
|
16 |
E6 Diagnostic_procedure:T9 |
|
|
17 |
T10 Biological_structure 93 102 abdominal |
|
|
18 |
R2 MODIFY Arg1:T10 Arg2:E6 |
|
|
19 |
T11 Disease_disorder 123 147 intraabdominal pathology |
|
|
20 |
E7 Disease_disorder:T11 |
|
|
21 |
A1 POLARITY E7 UNCERTAIN |
|
|
22 |
T12 Diagnostic_procedure 161 163 CT |
|
|
23 |
E8 Diagnostic_procedure:T12 |
|
|
24 |
T13 Biological_structure 171 178 abdomen |
|
|
25 |
R3 MODIFY Arg1:T13 Arg2:E8 |
|
|
26 |
T14 Nonbiological_location 200 211 institution |
|
|
27 |
R4 MODIFY Arg1:T14 Arg2:E8 |
|
|
28 |
T15 Detailed_description 229 259 standard venous phase protocol |
|
|
29 |
R5 MODIFY Arg1:T15 Arg2:E8 |
|
|
30 |
T16 Diagnostic_procedure 284 306 positive oral contrast |
|
|
31 |
E9 Diagnostic_procedure:T16 |
|
|
32 |
R6 SUB_PROCEDURE Arg1:E9 Arg2:E8 |
|
|
33 |
T17 Medication 317 342 barium sulfate suspension |
|
|
34 |
E10 Medication:T17 |
|
|
35 |
T18 Dosage 343 351 2.1% w/v |
|
|
36 |
R7 MODIFY Arg1:T18 Arg2:E10 |
|
|
37 |
T19 Detailed_description 353 365 Mallinckrodt |
|
|
38 |
R8 MODIFY Arg1:T19 Arg2:E10 |
|
|
39 |
R9 SUB_PROCEDURE Arg1:E10 Arg2:E9 |
|
|
40 |
T20 Medication 394 403 iopromide |
|
|
41 |
E11 Medication:T20 |
|
|
42 |
R10 SUB_PROCEDURE Arg1:E11 Arg2:E9 |
|
|
43 |
T21 Dosage 384 390 125 ml |
|
|
44 |
T22 Dosage 405 416 300 mg I/mL |
|
|
45 |
T23 Detailed_description 418 445 Ultravist, Bayer HealthCare |
|
|
46 |
R11 MODIFY Arg1:T23 Arg2:E11 |
|
|
47 |
R12 MODIFY Arg1:T21 Arg2:E11 |
|
|
48 |
R13 MODIFY Arg1:T22 Arg2:E11 |
|
|
49 |
T24 Administration 271 280 ingestion |
|
|
50 |
R14 MODIFY Arg1:T24 Arg2:E10 |
|
|
51 |
T25 Administration 371 380 injection |
|
|
52 |
R15 MODIFY Arg1:T25 Arg2:E11 |
|
|
53 |
T26 Coreference 456 458 CT |
|
|
54 |
E12 Coreference:T26 |
|
|
55 |
T27 Detailed_description 448 455 helical |
|
|
56 |
R16 MODIFY Arg1:T27 Arg2:E12 |
|
|
57 |
R17 IDENTICAL Arg1:E12 Arg2:E8 |
|
|
58 |
T28 Detailed_description 479 489 65-s delay |
|
|
59 |
R18 MODIFY Arg1:T28 Arg2:E12 |
|
|
60 |
T29 Detailed_description 499 533 64-slice GE Lightspeed VCT scanner |
|
|
61 |
R19 MODIFY Arg1:T29 Arg2:E12 |
|
|
62 |
T30 Detailed_description 535 568 GE Medical Systems; Milwaukee, WI |
|
|
63 |
R20 MODIFY Arg1:T30 Arg2:T29 |
|
|
64 |
T31 Diagnostic_procedure 571 585 Axial sections |
|
|
65 |
E13 Diagnostic_procedure:T31 |
|
|
66 |
R21 SUB_PROCEDURE Arg1:E13 Arg2:E12 |
|
|
67 |
T32 Biological_structure 593 600 abdomen |
|
|
68 |
R22 MODIFY Arg1:T32 Arg2:E13 |
|
|
69 |
T33 Sign_symptom 660 664 mass |
|
|
70 |
E14 Sign_symptom:T33 |
|
|
71 |
T34 Lab_value 610 615 large |
|
|
72 |
T35 Volume 617 628 18×22×22 cm |
|
|
73 |
R23 MODIFY Arg1:T35 Arg2:E14 |
|
|
74 |
R24 MODIFY Arg1:T34 Arg2:E14 |
|
|
75 |
T36 Detailed_description 630 643 heterogeneous |
|
|
76 |
T37 Biological_structure 644 659 retroperitoneal |
|
|
77 |
R25 MODIFY Arg1:T37 Arg2:E14 |
|
|
78 |
R26 MODIFY Arg1:T36 Arg2:E14 |
|
|
79 |
T38 Biological_structure 691 709 left adrenal gland |
|
|
80 |
R27 MODIFY Arg1:T38 Arg2:E14 |
|
|
81 |
T39 Detailed_description 721 754 multiple areas of macroscopic fat |
|
|
82 |
R28 MODIFY Arg1:T39 Arg2:E14 |
|
|
83 |
T40 History 780 852 no documented clinical or laboratory evidence of adrenal hormonal excess |
|
|
84 |
T41 Therapeutic_procedure 930 948 surgical resection |
|
|
85 |
E15 Therapeutic_procedure:T41 |
|
|
86 |
T42 Sign_symptom 969 973 mass |
|
|
87 |
E16 Sign_symptom:T42 |
|
|
88 |
T43 Biological_structure 956 968 left adrenal |
|
|
89 |
R29 MODIFY Arg1:T43 Arg2:E16 |
|
|
90 |
T44 Disease_disorder 1042 1066 adrenocortical carcinoma |
|
|
91 |
E17 Disease_disorder:T44 |
|
|
92 |
T45 Severity 1032 1041 low-grade |
|
|
93 |
R30 MODIFY Arg1:T45 Arg2:E17 |
|
|
94 |
T46 Diagnostic_procedure 994 1016 pathologic examination |
|
|
95 |
E18 Diagnostic_procedure:T46 |
|
|
96 |
* OVERLAP E1 E2 E3 E4 |
|
|
97 |
R31 BEFORE Arg1:E4 Arg2:E5 |
|
|
98 |
* OVERLAP E5 E6 E7 E8 E12 E13 E14 |
|
|
99 |
R32 BEFORE Arg1:E14 Arg2:E15 |
|
|
100 |
* OVERLAP E15 E16 |
|
|
101 |
R33 MODIFY Arg1:E16 Arg2:E15 |
|
|
102 |
R34 BEFORE Arg1:E16 Arg2:E18 |
|
|
103 |
* OVERLAP E18 E17 |